An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells

An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells

IntroductionOsteosarcoma (OSA) is an aggressive form of bone cancer in both dogs and humans. The treatment options for metastatic (stage III) OSA are currently limited and the prognosis is poor. Zoledronate, a second generation amino-bisphosphonate, is commonly used for palliation of cancer induced...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Yoshimi Iwaki, Stephanie E. S. Lindley, Noelle Bergman, Bruce F. Smith, Satyanarayana R. Pondugula
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Frontiers Media S.A. 2024-02-01
Σειρά:	Frontiers in Veterinary Science
Θέματα:	dogs osteosarcoma chemotherapy zoledronate combination effect
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fvets.2024.1327377/full

Παρόμοια τεκμήρια

Effects of neoadjuvant zoledronate and radiation therapy on cell survival, cell cycle distribution, and clinical status in canine osteosarcoma
ανά: Carissa J. Norquest, κ.ά.
Έκδοση: (2024-01-01)

Extracellular matrix production and oxygen diffusion regulate chemotherapeutic response in osteosarcoma spheroids
ανά: Isabel S. Sagheb, κ.ά.
Έκδοση: (2024-09-01)

Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
ανά: Aya Alsalih, κ.ά.
Έκδοση: (2021-07-01)

Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
ανά: P Madhuchandra, κ.ά.
Έκδοση: (2024-01-01)

An analysis of extraskeletal osteosarcoma based on the literature
ανά: De-Hui Wang, κ.ά.
Έκδοση: (2025-01-01)

MiRNAs in Canine and Human Osteosarcoma: A Highlight Review on Comparative Biomolecular Aspects
ανά: Leonardo Leonardi, κ.ά.
Έκδοση: (2021-02-01)

MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future?
ανά: Olivia Gourbault, κ.ά.
Έκδοση: (2020-09-01)

Biomimetic Collagen Membranes as Drug Carriers of Geranylgeraniol to Counteract the Effect of Zoledronate
ανά: Francisco Javier Manzano-Moreno, κ.ά.
Έκδοση: (2023-12-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
ανά: Nataliya Vladimirovna Toroptsova, κ.ά.
Έκδοση: (2011-06-01)

Effect of zoledronic acid on muscle metabolism in mice with osteoporosis combined with sarcopenia
ανά: Weilong Li, κ.ά.
Έκδοση: (2024-11-01)

Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial
ανά: Asif Hussain, κ.ά.
Έκδοση: (2023-01-01)

Zoledronic acid overdose in a two-year-old with osteogenesis imperfecta
ανά: Brandtly Yakey, κ.ά.
Έκδοση: (2023-12-01)

The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate
ανά: Silvia Ricchiuto, κ.ά.
Έκδοση: (2023-09-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
ανά: N. V. Toroptsova, κ.ά.
Έκδοση: (2021-10-01)

Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma
ανά: Dylan T. Ammons, κ.ά.
Έκδοση: (2025-02-01)

Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes
ανά: Joaquim Soares do Brito, κ.ά.
Έκδοση: (2023-06-01)

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
ανά: Jianfeng Sun, κ.ά.
Έκδοση: (2024-07-01)

Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
ανά: Stefan S. Bielack, κ.ά.
Έκδοση: (2024-06-01)

Immunophenotyping of an Unusual Mixed-Type Extraskeletal Osteosarcoma in a Dog
ανά: Hyo-Sung Kim, κ.ά.
Έκδοση: (2021-12-01)

Current Status and Prospects of Targeted Therapy for Osteosarcoma
ανά: Zunguo Hu, κ.ά.
Έκδοση: (2022-11-01)

Wrapped Up in Rarity: A Case of Pathologic Fracture-associated Telangiectatic Osteosarcoma
ανά: Mansimran Kaur, κ.ά.
Έκδοση: (2024-09-01)

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series
ανά: Hisaki Aiba, κ.ά.
Έκδοση: (2023-04-01)

Vertebral Osteosarcoma in Two Cats—Diagnosis, Treatment, and Outcome
ανά: Koen Maurits Santifort, κ.ά.
Έκδοση: (2023-11-01)

Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study
ανά: Elisa Tirtei, κ.ά.
Έκδοση: (2024-06-01)

What has changed in the last 25 years in osteosarcoma treatment? A single center experience
ανά: Eda Ataseven, κ.ά.
Έκδοση: (2023-02-01)

Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study
ανά: Jinkui Wang, κ.ά.
Έκδοση: (2023-06-01)

Craniofacial Effects of Zoledronic Acid on the Osteogenesis Imperfecta Mouse (−/−) Model of Severe Osteogenesis Imperfecta
ανά: Gaspard Jeannerod, κ.ά.
Έκδοση: (2024-11-01)

Demographic and Treatment Analysis of Periosteal Osteosarcoma
ανά: Michael C. Larkins
Έκδοση: (2024-12-01)

The dynamin inhibitor, dynasore, prevents zoledronate-induced viability loss in human gingival fibroblasts by partially blocking zoledronate uptake and inhibiting endosomal acidification
ανά: Jacob KIRBY, κ.ά.
Έκδοση: (2024-09-01)

Hyponatremia after intravenous zoledronic acid administration: A case report
ανά: Nafis Vural, κ.ά.
Έκδοση: (2023-12-01)

ZOLEDRONIC ACID ADMINISTRATION ENHANCES FRACTURE HEALING IN THE OSTEOPOROTIC FRACTURES IN OVARIECTOMIZED RABBITS
ανά: Cansabuncu Gokhan, κ.ά.
Έκδοση: (2019-05-01)

Oligopeptide modified ICG/Cisplatin@CaCO3 for targeted osteosarcoma NIR-II imaging guided multimodal therapy
ανά: Li-chen Ji, κ.ά.
Έκδοση: (2024-06-01)

A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma
ανά: Alessandro Comandone, κ.ά.
Έκδοση: (2021-02-01)

Posterior scleritis following a single infusion of zoledronate for osteoporosis: A case report and literature review
ανά: Dingling Ma, κ.ά.
Έκδοση: (2024-06-01)

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ
ανά: Ilaria Roato, κ.ά.
Έκδοση: (2023-10-01)

Expression of Sex Hormone Receptors in Canine Osteosarcoma
ανά: Kristyn N. Dilley, κ.ά.
Έκδοση: (2022-09-01)

Can zoledronic acid reduce the risk of cage subsidence after oblique lumbar interbody fusion combined with bilateral pedicle screw fixation in the elderly population? A retrospective study
ανά: Cong Jin, κ.ά.
Έκδοση: (2024-06-01)

Osteosarcoma cells can reproduce into tumorigenic cells by escaping chemotherapy-induced cell senescence
ανά: ZHANG Liang, LIU Ming-yong, LIU Peng, XUE Xin, ZHANG Liang-min, GUO Qiao-nan, ZHAO Jian-hua
Έκδοση: (2020-02-01)

Increased bone mass but delayed mineralization: in vivo and in vitro study for zoledronate in bone regeneration
ανά: Rongchang Wang, κ.ά.
Έκδοση: (2024-09-01)

A Case Report on Zoledronic Acid as Palliative Treatment in Carcinoma of Lung with Bone Metastasis
ανά: Sandhya Y., κ.ά.
Έκδοση: (2023-07-01)